Development of novel cellular systems for the study of chemo-resistance in Medulloblastoma.

Anti-mitotic drugs such as vincristine are a mainstay of current treatment regimens for multiple cancers affecting both adults and children, including medulloblastoma (MB). The clinical efficacy of these treatments is hampered by the emergence of drug-resistant clones following treatment, which can result in patient relapse. MB is a leading cause of cancer-related death in infants and children [1] with 5-year survival rate of 70%, although for patients with the most aggressive diagnosis, Group 3 (G3), this drops to 50% [2]

Grant Award – Kidscan Student Placement (2019 – 2020)

Funding Award – £2000.00

Funding Awarded to – Dr Caroline Topham

Research Location – University of Salford

Lead Researcher – Dr Caroline Topham